We are a UK molecular diagnostics company with a single conviction: that the most important decisions in transplant medicine deserve the clearest possible science.
Transplantation is one of medicine's great achievements, and one of its most delicate balancing acts. Too little vigilance and the immune system rejects the graft; too much and the patient is exposed to infection and harm. For decades, that balance has been managed with tools that are expensive, centralised, or a generation behind the science.
Scira exists to change that: to read the true molecular signal, to report it in numbers that can be trusted and compared, and to make it reachable far beyond the handful of centres that can afford today's tests.
Clarity is the difference between watching and knowing.
We separate what is validated from what is modelled, and we say which is which. In diagnostics, over-claiming is the fastest way to lose trust.
Transplant immunology is a field built by giants. We aim to advance it with respect, not to dismiss it, as the confident challenger rather than the brash disruptor.
A test that only reaches the wealthiest systems has not finished its job. We design for equity of access from the first line of code and chemistry.
Scira was founded by a consultant transplant physician who has lived the limits of today's diagnostics at the bedside and inside the diagnostics industry itself. That dual perspective, the clinical need and the science to meet it, sits at the centre of everything we build.
We are building a team of scientists, engineers and clinical partners who share the same standard: get it right, and make it clear.
